Ovarian disease is the 6th most basic malignancy worldwide among ladies in created nations and the most deadly of all gynecologic malignancies.(1) Currently, most ladies have propelled stage illness at the hour of determination. Regardless of forceful medical procedure and chemotherapy, the anticipation for these ladies is poor, with a 5-year endurance pace of under 30%. This poor result is expected to a limited extent to the absence of compelling avoidance and early identification techniques: when analyzed at a beginning period, the endurance rate is around 85–90%. In this manner, avoidance and early recognition are critical to conquering this illness. Except for oral contraceptives, there are no effective chemopreventive operators accessible.
Case Report: Journal of Cancer Clinical Trials
Case Report: Journal of Cancer Clinical Trials
Review Article: Journal of Cancer Clinical Trials
Review Article: Journal of Cancer Clinical Trials
Review Article: Journal of Cancer Clinical Trials
Review Article: Journal of Cancer Clinical Trials
Editorial: Journal of Cancer Clinical Trials
Editorial: Journal of Cancer Clinical Trials
Editorial: Journal of Cancer Clinical Trials
Editorial: Journal of Cancer Clinical Trials
Posters & Accepted Abstracts: Journal of Clinical Case Reports
Posters & Accepted Abstracts: Journal of Clinical Case Reports
Scientific Tracks Abstracts: Journal of Advanced Practices in Nursing
Scientific Tracks Abstracts: Journal of Advanced Practices in Nursing
Scientific Tracks Abstracts: Journal of Advanced Practices in Nursing
Scientific Tracks Abstracts: Journal of Advanced Practices in Nursing
Scientific Tracks Abstracts: Journal of Advanced Practices in Nursing
Scientific Tracks Abstracts: Journal of Advanced Practices in Nursing
Journal of Cancer Clinical Trials received 95 citations as per Google Scholar report